Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2023-06-26 Director's Dealing
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2023-06-26 English
FORM 4
Director's Dealing
2023-06-26 English
FORM 424B5
Capital/Financing Update Classification · 100% confidence The document is a Form 424B5 prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock by BioCardia, Inc. It details the terms of the offering, including the number of shares, pricing, use of proceeds, risk factors, and other offering-related information. This type of filing is a capital raising document used to update or supplement a previously filed prospectus and is not a financial report, earnings release, or management discussion. It is specifically related to financing activities and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a mere announcement but the actual prospectus supplement.
2023-06-22 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 21, 2023. It announces a securities purchase agreement involving the sale of common stock in a registered direct offering, including details about the offering price, number of shares, investors involved, and use of proceeds. The document includes legal opinions and the purchase agreement as exhibits. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The content focuses on a capital raising event and financing activity. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just an announcement of a report or certification. Hence, the classification is CAP with high confidence.
2023-06-21 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 20, 2023. It reports an event regarding the suspension of sales under a Controlled Equity Offering Sales Agreement. The content is an announcement of a financing-related event, specifically about the suspension of equity sales. The document length is 2734 characters, which is relatively short and contains no detailed financial statements or comprehensive financial data. It is not an earnings release or annual/interim report. The nature of the event relates to capital/financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-06-20 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 20, 2023. It announces that the FDA has completed review of a statistical analysis design supplement related to an ongoing pivotal study. The document includes a press release and does not contain financial statements or detailed financial data. It is a regulatory announcement about a clinical trial update and FDA review, not a financial report or earnings release. The document is relatively short (3744 characters) and serves as a regulatory filing to inform investors of a material event. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2023-06-20 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.